Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Illumina Laboratory Services, |
RCV000778876 | SCV000915274 | likely pathogenic | Upshaw-Schulman syndrome | 2018-10-30 | criteria provided, single submitter | clinical testing | The ADAMTS13 c.330+1G>A variant occurs in a canonical splice site (donor) and is therefore predicted to disrupt or distort the normal gene product. The c.330+1G>A variant is reported in two studies in which it is found in a compound heterozygous state with two different missense variants in two individuals with familial thrombotic thrombocytopenia purpura (Uchida et al. 2004; Park et al. 2008). The variant was absent from 66 Japanese controls, but is reported at a frequency of 0.000059 in the East Asian population of the Genome Aggregation Database. This is based on one allele in a region of good sequence coverage so the variant is presumed to be rare. Both affected individuals demonstrated less than three percent of plasma ADAMTS13 activity compared to controls (Uchida et al. 2004; Park et al. 2008). Functional studies using a minigene system demonstrated that the variant resulted in aberrant splicing as predicted (Uchida et al. 2004). Based on the evidence the c.330+1G>A variant is classified as likely pathogenic for familial thrombotic thrombocytopenia purpura disease. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. |
| Fulgent Genetics, |
RCV000778876 | SCV005681456 | pathogenic | Upshaw-Schulman syndrome | 2024-03-08 | criteria provided, single submitter | clinical testing |